LAWRENCE, Mass., Oct. 27, 2017 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, today announced that at a special
meeting of stockholders held today, the Company's stockholders
voted to adopt the previously announced Agreement and Plan of
Merger, dated August 7, 2017 (the
"Merger Agreement"), with Fresenius Medical Care Holdings, Inc.
("Fresenius"), whereby Fresenius will acquire NxStage through a
wholly-owned subsidiary of Fresenius. The approval of the Merger
Agreement fulfills an important condition for the full acquisition
of NxStage Medical, Inc.
Approximately 94% of the vote cast at today's special meeting of
stockholders voted in favor of the adoption of the Merger
Agreement. This represents approximately 72% of NxStage's total
outstanding shares of common stock as of the September 20, 2017 record date and constitutes a
majority of the outstanding shares of NxStage common stock entitled
to vote at the special meeting, as required to adopt the Merger
Agreement.
Upon completion of the merger, NxStage stockholders will be
entitled to received $30.00 in cash,
without interest, for each share of NxStage's common stock that
such stockholder owns. The merger, which is expected to be
completed in 2018, remains subject to additional customary closing
conditions, including regulatory review under the Hart-Scott-Rodino
Antitrust Improvements Act in the U.S.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics committed to the development of
innovative care delivery models for patients with ESRD. For more
information on NxStage and its products and services, please visit
the Company's websites at www.nxstage.com and
www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2017. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen
K. Sheppard, Esq.
ksheppard@nxstage.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/nxstage-announces-stockholder-approval-of-merger-agreement-with-fresenius-medical-care-300544857.html
SOURCE NxStage Medical, Inc.